Literature DB >> 12749547

Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness.

Jose E Martínez-Rodríguez1, Ling Lin, Alex Iranzo, David Genis, Maria J Martí, Joan Santamaria, Emmanuel Mignot.   

Abstract

STUDY
OBJECTIVE: Myotonic dystrophy type 1 is a multisystem disorder with myotonia, muscle weakness, cataracts, endocrine dysfunction, and intellectual impairment. This disorder is caused by a CTG triplet expansion in the 3' untranslated region of the DMPK gene on 19q13. Myotonic dystrophy type 1 is frequently associated with excessive daytime sleepiness, sharing with narcolepsy a short sleep latency and the presence of sleep-onset rapid eye movement periods during the Multiple Sleep Latency Test. Since narcolepsy is characterized by a dysfunction of the hypothalamic hypocretin system, we investigated whether patients with myotonic dystrophy type 1 with excessive daytime sleepiness have abnormalities in the hypocretin system. DESIGN/PARTICIPANTS: Six patients with myotonic dystrophy type 1 complaining of excessive daytime sleepiness and 13 healthy controls without a sleep disorder were included. The patients with myotonic dystrophy type 1 were evaluated using clinical interviews, nocturnal polysomnograms, and Multiple Sleep Latency Tests. All patients had a confirmed genetic diagnosis for DM1 and were HLA typed. Cerebrospinal fluid hypocretin-1 levels were measured using a direct radioimmunoassay in patients and controls.
SETTING: University hospital sleep laboratory.
INTERVENTIONS: N/A. MEASUREMENT AND
RESULTS: The mean sleep latency on Multiple Sleep Latency Tests was abnormal in all patients (< 5 minutes in 2, < or = 8 in 4) and 2 sleep-onset rapid eye movement periods were observed in 2 subjects. All patients were HLA-DQB1*0602 negative. Hypocretin-1 levels were significantly lower in patients versus controls (p < 0.001); 1 case with 2 sleep-onset rapid eye movement periods had hypocretin-1 levels in the range generally observed in narcolepsy (< 110 pg/mL). Three cases had intermediate levels (110-200 pg/mL). Hypocretin-1 levels did not correlate clinically with disease severity or duration or with subjective or objective sleepiness reports.
CONCLUSIONS: A dysfunction of the hypothalamic hypocretin system may mediate sleepiness and abnormal Multiple Sleep Latency Test results in patients with myotonic dystrophy type 1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749547     DOI: 10.1093/sleep/26.3.287

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  21 in total

1.  [The neurotransmitter, hypocretin. An overview].

Authors:  C Baumann; C Bassetti
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

2.  Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline.

Authors:  Douglas A McKim; Jeremy Road; Monica Avendano; Steve Abdool; Fabien Cote; Nigel Duguid; Janet Fraser; Fracois Maltais; Debra L Morrison; Colleen O'Connell; Basil J Petrof; Karen Rimmer; Robert Skomro
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

3.  Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study.

Authors:  Huan Yu; Luc Laberge; Isabelle Jaussent; Sophie Bayard; Sabine Scholtz; Morales Raoul; Michel Pages; Yves Dauvilliers
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

4.  Salivary biomarkers of physical fatigue as markers of sleep deprivation.

Authors:  Darren J Michael; Bianca Valle; Jennifer Cox; John E Kalns; Donovan L Fogt
Journal:  J Clin Sleep Med       Date:  2013-12-15       Impact factor: 4.062

Review 5.  Daytime sleepiness and myotonic dystrophy.

Authors:  Luc Laberge; Cynthia Gagnon; Yves Dauvilliers
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

Review 6.  [Sleep disorders in neurological diseases].

Authors:  S Kotterba
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

Review 7.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

8.  Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2.

Authors:  Erek M Lam; Paul W Shepard; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Stuart J McCarter; Michael H Silber; Bradley F Boeve; Eric J Olson; Virend K Somers; Margherita Milone
Journal:  Neurology       Date:  2013-06-07       Impact factor: 9.910

Review 9.  Neuromuscular disorders and sleep.

Authors:  Ibrahim Oztura; Christian Guilleminault
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

10.  Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2.

Authors:  Martina Minnerop; Eileen Luders; Karsten Specht; Jürgen Ruhlmann; Christiane Schneider-Gold; Rolf Schröder; Paul M Thompson; Arthur W Toga; Thomas Klockgether; Cornelia Kornblum
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.